Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial

Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate

(2017) Anna Migdalska-Richards et al.   SYNAPSE

A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers

(2017) Shi-Yu Yang et al.   Stem Cell Reports

Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice

(2016) Anna Migdalska-Richards et al.   ANNALS OF NEUROLOGY

Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study

(2016) Aya Narita et al.   Annals of Clinical and Translational Neurology

Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders

(2015) Giancarlo Parenti et al.   MOLECULAR THERAPY

Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease

(2014) Karen E. Murphy et al.   BRAIN

Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells

(2014) Alisdair McNeill et al.   BRAIN

Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators

(2014) Ania C. Muntau et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Cognitive impairment and dementia in Parkinson's disease: Practical issues and management

(2014) Murat Emre et al.   MOVEMENT DISORDERS

The neurobiological basis of cognitive impairment in Parkinson's disease

(2014) Glenda M. Halliday et al.   MOVEMENT DISORDERS

Priority setting partnership to identify the top 10 research priorities for the management of Parkinson's disease

(2014) Katherine H O Deane et al.   BMJ Open

The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort

(2013) Caroline H Williams-Gray et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Predictors of Parkinson's disease dementia: Towards targeted therapies for a heterogeneous disease

(2013) Sarah F. Moore et al.   PARKINSONISM & RELATED DISORDERS

Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies

(2013) S. Pablo Sardi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains

(2012) Matthew E. Gegg et al.   ANNALS OF NEUROLOGY

Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease

(2012) Ari Zimran et al.   BLOOD CELLS MOLECULES AND DISEASES

The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice

(2012) Zhuo Luan et al.   BRAIN & DEVELOPMENT

The link between the GBA gene and parkinsonism

(2012) Ellen Sidransky et al.   LANCET NEUROLOGY

Donepezil in Parkinson's disease dementia: A randomized, double-blind efficacy and safety study

(2012) Bruno Dubois et al.   MOVEMENT DISORDERS

Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies

(2011) Joseph R. Mazzulli et al.   CELL

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

(2011) Olivier Rascol et al.   LANCET NEUROLOGY

Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models

(2011) Y.H. Xu et al.   MOLECULAR GENETICS AND METABOLISM

CNS expression of glucocerebrosidase corrects  -synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy

(2011) S. P. Sardi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher Disease

(2009) Gustavo H. B. Maegawa et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease

(2009) Paolo Barone et al.   MOVEMENT DISORDERS

Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: A biological link between Gaucher disease and parkinsonism

(2009) Amy B. Manning-Boğ et al.   NEUROTOXICOLOGY

A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease

(2009) C. Warren Olanow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ambroxol in the 21st century: pharmacological and clinical update

(2008) Mario Malerba et al.   Expert Opinion on Drug Metabolism & Toxicology

Parkinson's disease-cognitive rating scale: A new cognitive scale specific for Parkinson's disease

(2008) Javier Pagonabarraga et al.   MOVEMENT DISORDERS

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results

(2008) Christopher G. Goetz et al.   MOVEMENT DISORDERS

Dementia and survival in Parkinson disease: A 12-year population study

(2008) T. C. Buter et al.   NEUROLOGY